556 Publications Available
April 08, 2019
Nature Communications

CTD2 scientists at Broad Institute integrated genome-wide CRISPR screening and lipidomic profiling and identified the hypoxia-inducible factor pathways as an intrinsic vulnerability to ferroptosis. This vulnerability can be exploited by inhibiting glutathione peroxidase 4 in clear-cell carcinomas.

April 05, 2019

Perspective on the role of immune system in different tissues and how it contributes to disease when the prototype gets dysregulated or dysfunctional.

March 22, 2019

Review on the mechanisms of regulating oncogenic RAS signaling pathway in cancer and strategies for drugging “undruggable” targets.

March 21, 2019
Cell Chemical Biology

Scientists at the Emory University CTD2 Center developed the High-Throughput immunomodulator Phenotypic (HTiP) screening platform to explore PPI inhibitors, as immunomodulators. This screening identified the Inhibitor of Apoptosis Protein (IAP) as anti-tumor immunity enhancers.

March 21, 2019
Cancer Research

Dana-Farber Cancer Institute scientists analyzed data from genome-wide RNAi and CRISPR-Cas9 screens. Results of this study showed the hypoxia-inducing factor, EGLN1, as a preferential and druggable cancer dependency in a subset of cancer cell lines.

March 18, 2019
Cancer Cell

Bioinformatics analysis of The Cancer Genome Atlas (TCGA) data identifies focal adhesion kinase as a potential therapeutic target for uveal melanoma.

March 15, 2019
Cancer Discovery

Patient-derived in vitro and in vivo model systems discovered novel gene fusion, LAMTOR1-AKT1, as a tumorigenic driver in pediatric epithelioid neoplasm.

March 12, 2019

Integration of genetic and chemical screens identified a synthetic lethal relationship between SMARCB1-deficient cancers and the ubiquitin-proteasome system.

March 07, 2019

Concurrent measurement of single cell expression in tumor cells and tumor-infiltrating lymphocytes revealed novel biological insights of the tumor microenvironment; provides basis for developing novel therapeutic targets in lymphoma.